#IDIBELLseminars: C9orf72 FTD/ALS: mechanisms and therapeutic approaches
A GGGGCC repeat expansion in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS)…
International Open Access Week 2022 – Webinars
-
from 24 to 30 October
#IDIBELLfellows: Romina Miranda / Marta Valle
07/10/2020 15:00-16:00
Room 205 – Nou aulari UB-Bellvitge
Microsoft Teams Meeting
#IDIBELLconnect: Novel clinical and translational research approaches to mesothelioma, an orphan tumor
Ernest Nadal
Group Leader at Bellvitge Biomedical Research Institute (IDIBELL), Clinical Research in Solid Tumors Group, Oncobell Program
Head of Section of Thoracic, Brain and Head and Neck Tumors, Catalan Institute of Oncology (ICO), Department of Medical Oncology
Associate Professor, University of Barcelona, Department of Clinical Sciences, Campus Bellvitge
09/10/2020 13:00-14:00
Microsoft Teams Meeting
Career Day 2020
21/10/2020 -
21-22 October 2020
This event is being held online
La recerca en temps de pandèmia
Dra. Maria Ángeles Domínguez
Dr. Xavier Solanich
21/10/2020 19:00-
VII Programa de excelencia en el abordaje del paciente con EM de alta actividad
Unitat EM HUB
22/10/2020 -
22-23 Octubre 2020
Sala d’actes Bellvitge University hospital 9.00h
#IDIBELLconnect: RANK a novel therapeutic target in breast cancer
Speaker Eva Gonzalez-Suarez
Transformation and Metastasis Group, Oncobell Program
06/11/2020 13:00-14:00
PhD Day 2020
12/11/2020 -
12-13 November 2020
this event is being held online
#IDIBELLconnect: Generation of protective immunity against infections by removing non-neutralizing/blocking antibodies
Rafael Máñez
Group Leader at the Bellvitge Biomedical Research Institute (IDIBELL), Innate Immunity and Pathology of the Critical Patient Group, Infectious disease and transplantation Program
Director of Intensive Care Department at Bellvitge University Hospital
20/11/2020 13:00-14:00
Microsoft Teams Meeting
Thesis: Osteoarticular infections: insights on bacteraemic clinical forms and antimicrobial alternatives against Pseudomonas aeruginosa from a translational perspective
By Joan Gómez Junyent
Directors: Javier Ariza Cardenal i Oscar Murillo Rubio
24/11/2020 12:00-
Xerrades Sinergia
Òscar Martínez Tirado
Marta Barrachina
Gabriela Jiménez
Anna Veiga
Esteve Fernandez
Susana Jiménez
Rafael Máñez
Mònica Povedano
Miquel Àngel Pujana
Laia Alemany
Montse Nacher
28/11/2020 10:00-19:00
Online i en directe:
https://sinergia.l-h.cat/
#IDIBELLconnect: The mTOR-LARP1 axis and the anabolic reservoir of tumor cells: A new therapeutic target in colorectal cancer and beyond
Antonio Gentilella
Metabolism and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)
Department of Physiology and Biochemistry, Faculty of Pharmacy, University of Barcelona
04/12/2020 13:00-14:00
Microsoft Teams Meeting
#IDIBELLconnect: Immunotherapeutic potential of oncolytic Vaccinia viruses
Juan Jose Rojas
Bellvitge Biomedical Research Institute (IDIBELL)
Unitat d’Immunologia, Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona
18/12/2020 13:00-14:00
Microsoft Teams Meeting
- 1
- 2
- 3
- …
- 32
- Entrades següents »
#Facultyseminar: Macrophage-epithelial crosstalk and cellular memory govern intestinal regeneration
Jordi Guiu’s laboratory (p-cmrc.cat/research/guiu-group) focuses on understanding the behavior of intestinal epithelial cells during homeostasis and in response…
Buscando cómo mejorar la movilidad de los pacientes con EspA
Formación continuada en EspA 19 y 20 de diciembre de 2024 Servicio de Reumatologia Hospital Moisès Broggi,…
Thesis: Unraveling the molecular basis of the metastatic process in Ewing sarcoma: insights into the role of LOXHD1 and PARP14
Friday december 13 2024, Sala de graus de l’Aulari de la UB – Campus Bellvitge, 11:00 h…
7th ICO-WHO Symposium on tobacco control
Taking decisive action in tobacco control Barcelona, December 9, 2024 Pau Viladiu Auditorium, Catalan Institute of Oncology…
IDIBELLfellows: Pedro Fuentes & Sara Montserrat
LARP1-Mediated Drug Tolerance in Colorectal Cancer: A Non-Genetic Mechanism Underlying Chemoresistance and Tumor Relapse Pedro Fuentes –…
Thesis: New therapeutic approaches to target myofibroblast activation in liver pathologies: fibrosis and cholangiocarcinoma
Monday december 16 2024, Sala d’actes, Pavelló de Govern, UB, 11:00 h New therapeutic approaches to target…
Protein stability and beyond to elucidate hypoxia signaling
“Protein stability and beyond to elucidate hypoxia signaling” Edurne Berra – CICbioGUNE, Bilbao Hosted by Francesc Viñals –…
Reunión con pacientes con Esclerosis múltiple del hospital de Sant Joan Despí Moisès Broggi
PROGRAMA 16:00 h Introducción a la reunión y bienvenida Dra. Ester Moral, jefa de Servicio de Neurología…
#IDIBELLfellows: Anne-Sophie Chong / Luca Ruvo
Tracing the Molecular Route to Progression in Defective miRNA Biogenesis Benign vs Malignant Thyroid Lesions Anne-Sophie Chong…
- 1
- 2
- 3
- …
- 32
- Entrades següents »